TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

Reimagine your life with fewer HAE attacks

Lexi, a real TAKHZYRO® patient, stretching.
Lexi

In the 6.5-month clinical study, people taking TAKHZYRO 300mg every 2 weeks had

Down arrow icon.
87%

FEWER
ATTACKS

on average compared with placebo

TAKHZYRO helped prevent attacks in the 6.5-month clinical study that led to FDA approval. In this initial study, which included 125 people with hereditary angioedema (HAE), people taking TAKHZYRO every 2 weeks also had 83% fewer moderate or severe attacks and 87% fewer attacks that needed acute treatment compared to placebo.

After completing the initial study, ~97% of people in the TAKHZYRO study groups chose to enroll in a long-term, open-label extension study that lasted 2.5 years. This study included 212 people with HAE, of which 109 patients participated in the initial clinical study. Long-term safety of TAKHZYRO was the primary focus of this study.

In the long-term, open-label study, people taking TAKHZYRO for an average of 30 months had similar results.
87% fewer attacks on average compared with baseline. People also had 84% fewer moderate or severe attacks and 93% fewer attacks that needed acute treatment compared with baseline.

Baseline means a person's attack rate before beginning treatment in either the clinical study or the long-term, open-label study.

See Lexi's Reimagine Story

View Transcript

LEXI: I could have a small hand swell on a Monday, and then finally get over that, and by Wednesday or Thursday, my feet may be irritated, or my ankle may have just had a light swell. Hi, I’m Lexi, and this is my reimagine story. I’m a social media manager in Louisville, and I’m also getting my master’s degree. It’s been busy, but I love my job, and I love being in school. I was diagnosed with HAE when I was 7 years old.

LEXI: My father has it, his sister has it, and his father has it, so we were on alert. The first HAE attack I remember was a stomach attack. I was on the couch hugging myself, wondering when it would be over. After that, I started having attacks more frequently. I missed school and had to rest a lot, which was really frustrating, because I wanted to do what the other kids were doing, like playing volleyball. My best friends played, and I was so mad that I couldn’t do it. It sounds silly, but at that age, everything is really serious.

LEXI: Fortunately, when I was older, there were more treatment options available to help me manage my HAE. I went to college, met my boyfriend, D.J., and started a career. We even adopted a dog. As time went by, I felt that I was ready to take more control of my health and treatment decisions. I was interested when I heard about TAKHZYRO®, a once-every-other-week subcutaneous injection used to prevent HAE attacks in people 12 years of age and older.

LEXI: Before deciding to try another option, my doctor and I talked about every aspect of the treatment, including the potential risks associated with TAKHZYRO, including serious side effects, like allergic reactions, and the more common ones, like injection site reactions, upper respiratory infections, and headaches. We also discussed if it was a good option for me. Remember, not everyone is the same. These days, D.J. and I are on the go a lot. We love taking our dog out and going to concerts and vintage shopping. Basically, we’re huge on experiences, and that means traveling, too, most recently to New York City.

LEXI: Fitness is a big part of my life as well. I love jogging and try to get out as much as I can. Spin classes, too. When I was a kid, I didn’t know what would happen. I hated having HAE. But as treatment options became more available, I felt more positive, and that’s what I would say to others. Be positive. You may have HAE, but HAE does not have you. On average, I would have about one to two attacks per week. Since taking TAKHZYRO, the frequency of my attacks has gone down. If you are interested in learning more about reimagining your life with HAE, talk to your healthcare provider to see if TAKHZYRO is right for you.

NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age. TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, and/or hives.

NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.

On average, I would have about one to two attacks per week. Since taking TAKHZYRO, the frequency of my attacks has gone down.
Lexi Real TAKHZYRO patient
Individual results may vary.

TAKHZYRO was evaluated in one of the longest preventive studies in HAE

TAKHZYRO helped prevent HAE attacks:

  • Whether previous attacks were frequent or infrequent
  • Whether or not people had a history of throat attacks
  • Regardless of whether preventive therapy had been used before

TAKHZYRO safety information

TAKHZYRO may cause serious side effects, including allergic reaction. Call your doctor or get emergency help right away if you have symptoms of an allergic reaction.

Injection site reactions were the most common side effects of TAKHZYRO

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of TAKHZYRO.

For more information, ask your healthcare provider or pharmacist.

Most common side effects in the 6.5-month clinical study
TAKHZYRO
(84 people)*
Placebo
(41 people)
Injection site reactions
52%
34%
Pain
43%
29%
Redness
10%
2%
Bruising
7%
0%
Upper respiratory infection
29%
32%
Headache
21%
22%
Rash
7%
5%
Muscle pain
5%
0%
Dizziness
6%
0%
Diarrhea
5%
5%

*Included all people treated with TAKHZYRO (300 mg every 2 weeks, 300 mg every 4 weeks, or 150 mg every 4 weeks) in the clinical study.

The most common side effects (occurring in ≥10% of people) seen in the long-term, open-label injection site reactions (including pain, redness, and bruising), upper respiratory infections, headache, and diarrhea.

Most common side effects in the 2.5-year, long-term, open-label study
TAKHZYRO 300 mg every 2 weeks (212 people)
Injection site pain
47%
Viral upper respiratory tract infection
42%
Upper respiratory tract infection
26%
Headache
25%
Injection site redness
17%
Joint pain
13%
Injection site bruising
12%
Back pain
12%
Diarrhea
11%
Sinus infection
11%
Influenza
10%
Nausea
10%
Urinary tract infection
10%

Explore more information on TAKHZYRO safety and side effects.

See safety info

Speech bubbles icon.

See how TAKHZYRO works to prevent HAE attacks.

WATCH A VIDEO